| 1 | Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial 2024, 12, e008189 | | 21 | Citations (PDF) |
| 2 | A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer | 6.5 | 3 | Citations (PDF) |
| 3 | Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer | 2.1 | 2 | Citations (PDF) |
| 4 | A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results | 25.6 | 26 | Citations (PDF) |
| 5 | A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer | 6.4 | 0 | Citations (PDF) |
| 6 | CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors | 40.1 | 10 | Citations (PDF) |
| 7 | Germline <i>EGFR</i> Mutations and Familial Lung Cancer | 17.1 | 16 | Citations (PDF) |
| 8 | Exogenous Sequences in Tumors and Immune Cells (Exotic): A Tool for Estimating the Microbe Abundances in Tumor RNA-seq Data | 3.0 | 5 | Citations (PDF) |
| 9 | Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy | 2.8 | 19 | Citations (PDF) |
| 10 | Small cell lung cancer: Subtypes and therapeutic implications | 14.2 | 34 | Citations (PDF) |
| 11 | Illness perception profiles and psychological and physical symptoms in newly diagnosed advanced non-small cell lung cancer. | 3.0 | 20 | Citations (PDF) |
| 12 | Association of Allostatic Load With Overall Mortality Among Patients With Metastatic Non–Small Cell Lung Cancer | 7.2 | 18 | Citations (PDF) |
| 13 | Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results | 25.6 | 118 | Citations (PDF) |
| 14 | Metabolic reprogramming by adenosine antagonism and implications in non-small cell lung cancer therapy | 7.2 | 6 | Citations (PDF) |
| 15 | Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial | 25.6 | 137 | Citations (PDF) |
| 16 | Utility of cell-free DNA from bronchial washing fluid in diagnosis and genomic determination for radiology-suspected pulmonary nodules | 5.7 | 3 | Citations (PDF) |
| 17 | Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a multicenter, open-label, randomized, controlled phase III trial | 0.9 | 20 | Citations (PDF) |
| 18 | Advances in epigenetic therapeutics with focus on solid tumors | 4.3 | 72 | Citations (PDF) |
| 19 | Genomic and Transcriptomic Characterization of Relapsed SCLC Through Rapid Research Autopsy | 1.0 | 5 | Citations (PDF) |
| 20 | Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non–small cell lung cancers | 11.3 | 14 | Citations (PDF) |
| 21 | STK11/LKB1 Loss of Function Is Associated with Global DNA Hypomethylation and <i>S</i>-Adenosyl-Methionine Depletion in Human Lung Adenocarcinoma | 0.6 | 8 | Citations (PDF) |
| 22 | Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung | 8.5 | 15 | Citations (PDF) |
| 23 | Genetic Ancestry Affects Somatic Alterations in Lung Cancers | 26.4 | 0 | Citations (PDF) |
| 24 | The International Association for the Study of Lung Cancer Molecular Database Project: Objectives, Challenges, and Opportunities | 1.1 | 10 | Citations (PDF) |
| 25 | Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors | 1.1 | 65 | Citations (PDF) |
| 26 | Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis | 3.7 | 6 | Citations (PDF) |
| 27 | Lung cancer-associated T cell repertoire as potential biomarker for early detection of stage I lung cancer | 2.1 | 12 | Citations (PDF) |
| 28 | Comparison of Tumor Microenvironments Between Primary Tumors and Brain Metastases in Patients With NSCLC | 1.0 | 10 | Citations (PDF) |
| 29 | Linear Endobronchial Ultrasound in the Era of Personalized Lung Cancer Diagnostics—A Technical Review | 2.6 | 5 | Citations (PDF) |
| 30 | Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-β | 13.1 | 88 | Citations (PDF) |
| 31 | Newly diagnosed patients with advanced non-small cell lung cancer: A clinical description of those with moderate to severe depressive symptoms | 2.1 | 28 | Citations (PDF) |
| 32 | Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib | 2.1 | 32 | Citations (PDF) |
| 33 | Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer | 2.7 | 34 | Citations (PDF) |
| 34 | Verification of a Blood-Based Targeted Proteomics Signature for Malignant Pleural Mesothelioma | 0.9 | 7 | Citations (PDF) |
| 35 | Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer | 4.7 | 12 | Citations (PDF) |
| 36 | Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications | 3.0 | 46 | Citations (PDF) |
| 37 | TTF-1 Positive Primary Small Cell Carcinoma of the Breast: A Case Report and Review of the Literature | 4.0 | 14 | Citations (PDF) |
| 38 | Circulating MicroRNAs and Extracellular Vesicle–Containing MicroRNAs as Response Biomarkers of Anti–programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Therapy in NSCLC | 1.1 | 59 | Citations (PDF) |
| 39 | Minimally Invasive Lobectomy for Residual Primary Tumors of Advanced Non–Small-Cell Lung Cancer After Treatment With Immune Checkpoint Inhibitors: Case Series and Clinical Considerations | 2.8 | 8 | Citations (PDF) |
| 40 | Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma | 2.1 | 13 | Citations (PDF) |
| 41 | RANBP9 as potential therapeutic target in non-small cell lung cancer | 0.7 | 1 | Citations (PDF) |
| 42 | Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers | 2.4 | 86 | Citations (PDF) |
| 43 | Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater | 2.1 | 48 | Citations (PDF) |
| 44 | Co-Expression Analysis Reveals Mechanisms Underlying the Varied Roles of NOTCH1 in NSCLC | 1.1 | 14 | Citations (PDF) |
| 45 | Identification of Recurrent Activating<i>HER2</i>Mutations in Primary Canine Pulmonary Adenocarcinoma | 6.4 | 30 | Citations (PDF) |
| 46 | DLL3: an emerging target in small cell lung cancer | 24.7 | 132 | Citations (PDF) |
| 47 | The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non–Small Cell Lung Cancer | 1.1 | 17 | Citations (PDF) |
| 48 | Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis | 3.0 | 25 | Citations (PDF) |
| 49 | Novel mechanism of resistance to targeted therapies in lung cancer | 2.0 | 1 | Citations (PDF) |
| 50 | The Addition of Chemotherapy to Radiation Therapy Improves Survival in Elderly Patients with Stage III Non–Small Cell Lung Cancer | 1.1 | 59 | Citations (PDF) |
| 51 | Lung Cancer Patients with Germline Mutations Detected by Next-Generation Sequencing and/or Liquid Biopsy | 1.1 | 16 | Citations (PDF) |
| 52 | Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer | 1.1 | 147 | Citations (PDF) |
| 53 | Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database | 2.9 | 20 | Citations (PDF) |
| 54 | Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET–Rearranged Lung Cancers | 1.1 | 156 | Citations (PDF) |
| 55 | Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non–Small-cell Lung Cancer | 2.8 | 100 | Citations (PDF) |
| 56 | Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non–Small-Cell Lung Cancer | 2.8 | 35 | Citations (PDF) |
| 57 | Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC | 1.1 | 511 | Citations (PDF) |
| 58 | RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients | 6.6 | 12 | Citations (PDF) |
| 59 | Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC | 14.1 | 67 | Citations (PDF) |
| 60 | Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non–small-cell Lung Cancer: A Retrospective Study | 2.8 | 42 | Citations (PDF) |
| 61 | The effect of forced expression of mutated <i>K‐RAS</i> gene on gastrointestinal cancer cell lines and the IGF‐1R targeting therapy | 3.2 | 5 | Citations (PDF) |
| 62 | First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer | 25.5 | 2,035 | Citations (PDF) |
| 63 | A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma | 0.6 | 25 | Citations (PDF) |
| 64 | Costs of Diagnostic Assessment for Lung Cancer: A Medicare Claims Analysis | 2.8 | 85 | Citations (PDF) |
| 65 | Non-small cell lung cancer genomics around the globe: focus on ethnicity | 1.3 | 4 | Citations (PDF) |
| 66 | Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting | 2.5 | 77 | Citations (PDF) |
| 67 | The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016 | 1.1 | 168 | Citations (PDF) |
| 68 | Treatment Patterns for Advanced Non–Small-cell Lung Cancer After Platinum-containing Therapy in U.S. Community Oncology Clinical Practice | 2.8 | 17 | Citations (PDF) |
| 69 | Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1 Antibodies | 1.1 | 62 | Citations (PDF) |
| 70 | Aquaporin 11 variant associates with kidney disease in type 2 diabetic patients | 3.4 | 18 | Citations (PDF) |
| 71 | Scientific Advances in Lung Cancer 2015 | 1.1 | 231 | Citations (PDF) |
| 72 | Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer | 1.1 | 198 | Citations (PDF) |
| 73 | PDL1 Regulation by p53 via miR-34 | 5.1 | 499 | Citations (PDF) |
| 74 | Non-small-cell lung cancer | 24.7 | 720 | Citations (PDF) |
| 75 | Genomic Characterization of Non–Small-Cell Lung Cancer in African Americans by Targeted Massively Parallel Sequencing | 17.1 | 41 | Citations (PDF) |
| 76 | Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer | 7.1 | 11 | Citations (PDF) |
| 77 | Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer | 17.1 | 988 | Citations (PDF) |
| 78 | Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy | 0.6 | 47 | Citations (PDF) |
| 79 | Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma | 0.6 | 15 | Citations (PDF) |
| 80 | LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT | 1.1 | 66 | Citations (PDF) |
| 81 | EGFR Blockade Enriches for Lung Cancer Stem–like Cells through Notch3-Dependent Signaling | 0.6 | 101 | Citations (PDF) |
| 82 | Serum Proteomic Biomarkers 2014, , 90-109 | | 0 | Citations (PDF) |
| 83 | From the Guest Editors | 1.9 | 0 | Citations (PDF) |
| 84 | VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab | 2.1 | 44 | Citations (PDF) |
| 85 | VEGF as a Mediator of Tumor-Associated Immunodeficiency | 2.8 | 303 | Citations (PDF) |
| 86 | Lung Cancer Stem Cells and Their Clinical Implications | 6.7 | 9 | Citations (PDF) |
